Are Wall Street Analysts Predicting DaVita Stock Will Climb or Sink?

With a market cap of $14.2 billion, DaVita Inc. (DVA) is a leading provider of dialysis services in the United States, specializing in the treatment of patients with chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and offers a range of related medical services, including outpatient and inpatient dialysis, laboratory testing, and disease management.

Shares of the dialysis specialist have outperformed the broader market over the past 52 weeks. DVA has climbed 58.2% over this time frame, while the broader S&P 500 Index ($SPX) has gained 20.7%. Moreover, DVA stock has risen 16.2% on a YTD basis, compared to SPX's 3.2% YTD gain.